SALT LAKE CITY, July 6, 2011 /PRNewswire/ -- As part of its ongoing efforts to improve the quality of care and to moderate healthcare costs for patients diagnosed with scoliosis, Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, today announced that it has signed a multi-year agreement with the Shriners Hospitals for Children®.
The agreement focuses on providing access to the SCOLISCORE™ AIS Prognostic Test to patients diagnosed with Adolescent Idiopathic Scoliosis and meet the appropriate indications for use*, regardless of their ability to pay for the test. The agreement applies to all of the Shriners Hospitals for Children® in the United States, Canada and Mexico.
When a child is diagnosed with mild AIS, an abnormal curvature of the spine, it is often difficult for physicians to predict if the curve will progress to a more severe form of the condition, which may require surgery or other treatments. Now, the SCOLISCORE Test is helping to reduce the uncertainty of whether or not a curve will progress to a curve larger than 40 degrees, considered possibly needing a fusion, and may help low-risk patients reduce the need for repeated doctor visits, physical examinations, and years of frequent x-rays.
The SCOLISCORE Test was developed by utilizing a genome-wide association study that identified a panel of genetic markers associated with severe curve progression. The scoliosis research used in the development of this test included collecting DNA samples from over 10,000 patients from over 100 IRB approved clinical sites throughout the world. The test was then further validated in three separate clinical trials.
"This is a significant corporate commitment on our part to provide the SCOLISCORE Test to assist many of the Shriners patients," said John Climaco, Axial Biotech's President and CEO. "We fully support the mission of the Shrin
|SOURCE Axial Biotech, Inc.|
Copyright©2010 PR Newswire.
All rights reserved